The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
D000740:Anemia / Q000188:drug therapy / Q000191:economics / Q000209:etiology; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use; D001374:Azacitidine / Q000191:economics / Q000627:therapeutic use; D017281:Cost of Illness; D003365:Costs and Cost Analysis; D000068256:Darbepoetin alfa; D003661:Decision Support Techniques; D003676:Deferoxamine / Q000191:economics / Q000627:therapeutic use; D016527:Drug Costs / Q000706:statistics & numerical data*; D004358:Drug Therapy / Q000191:economics; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use; D006397:Hematinics / Q000008:administration & dosage / Q000191:economics*; D006801:Humans; D007502:Iron Chelating Agents / Q000191:economics / Q000627:therapeutic use; D000077269:Lenalidomide; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000188:drug therapy* / Q000191:economics; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins; D017262:Siderophores / Q000191:economics / Q000627:therapeutic use; D013792:Thalidomide / Q000031:analogs & derivatives / Q000191:economics; D014481:United States
D000970:Antineoplastic Agents; D006397:Hematinics; D007502:Iron Chelating Agents; D011994:Recombinant Proteins; D017262:Siderophores; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D013792:Thalidomide; D000068817:Epoetin Alfa; D000077269:Lenalidomide; D003676:Deferoxamine; D001374:Azacitidine